This TB-500 + MGF + Ipamorelin peptide blend contains 0.75 mg of TB-500, 0.6 mg of MGF, and 0.75 mg of Ipamorelin, providing a multi-pathway research tool for studies involving cellular repair, growth-signaling modulation, and pituitary-driven GH release. TB-500 (a synthetic Thymosin Beta-4 fragment) is commonly used to examine actin regulation and cell-migration behavior. MGF, a splice variant of the IGF-1 gene, supports research focused on localized anabolic signaling and cellular recovery processes. Ipamorelin is a selective GHSR agonist evaluated for targeted GH-axis activation under controlled laboratory conditions.
Researchers rely on this combination to model intersecting pathways that influence structural cellular behavior and endocrine signaling. The TB-500 + MGF + Ipamorelin peptide blend enables mechanistic analysis of how cytoskeletal activity, growth-factor responses, and pituitary stimulation may interact or contribute independently to experimental outcomes.
Scientific teams typically select this blend for:
Studying actin-linked cell migration and repair mechanisms
Mapping localized IGF-related signaling responses
Analysing selective GH-secretion pathways in vitro or ex vivo
Comparing multi-component effects with isolated peptide exposure
Because each component provides well-defined behavior in controlled environments, the blend supports reproducible mechanistic work and structured dose-response analysis. Its 3-pathway design offers flexibility for integrated cellular and endocrine studies requiring precise timing and clean data interpretation.
This peptide blend is supplied as a high-purity laboratory reagent intended only for qualified scientific professionals. It is not approved for human or veterinary administration, therapeutic use, diagnostic application, or clinical procedures. All handling must comply with institutional biosafety regulations and relevant research guidelines.
For research use only. Not for human consumption.
Researchers rely on this combination to model intersecting pathways that influence structural cellular behavior and endocrine signaling. The TB-500 + MGF + Ipamorelin peptide blend enables mechanistic analysis of how cytoskeletal activity, growth-factor responses, and pituitary stimulation may interact or contribute independently to experimental outcomes.
Scientific teams typically select this blend for:
Studying actin-linked cell migration and repair mechanisms
Mapping localized IGF-related signaling responses
Analysing selective GH-secretion pathways in vitro or ex vivo
Comparing multi-component effects with isolated peptide exposure
Because each component provides well-defined behavior in controlled environments, the blend supports reproducible mechanistic work and structured dose-response analysis. Its 3-pathway design offers flexibility for integrated cellular and endocrine studies requiring precise timing and clean data interpretation.
This peptide blend is supplied as a high-purity laboratory reagent intended only for qualified scientific professionals. It is not approved for human or veterinary administration, therapeutic use, diagnostic application, or clinical procedures. All handling must comply with institutional biosafety regulations and relevant research guidelines.
For research use only. Not for human consumption.
| Type | Synthetic compound |
|---|---|
| Category | Research Compound |
| Purity | ≥99% |
| Form | Lyophilized powder |
-20°C · 24+ months
2–8°C · ~30 days
Third-party tested for purity and quality.
| Variant | GLP3-RT 10mg |
|---|---|
| Lot # | REF0001 |
| Labeled | 20mg |
| Actual | 22.61mg |
| Tested | APR 15, 2026 |
Triple–Hormone-Receptor Agonist GLP-3 (RT) for Obesity — A Phase 2 Trial
2023
DOI: 10.1056/NEJMoa2301972
· Jastreboff AM, et al.
Triple–Hormone-Receptor Agonist GLP-3 (RT) for Obesity — A Phase 2 Trial
2023
DOI: 10.1056/NEJMoa2301972
· Jastreboff AM, et al.
Triple–Hormone-Receptor Agonist GLP-3 (RT) for Obesity — A Phase 2 Trial
2023
DOI: 10.1056/NEJMoa2301972
· Jastreboff AM, et al.
Not a researcher? Exit
